Edition:
India

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.26EUR
9:05pm IST
Change (% chg)

€0.00 (+0.00%)
Prev Close
€4.26
Open
€4.34
Day's High
€4.34
Day's Low
€4.24
Volume
22,796
Avg. Vol
66,804
52-wk High
€5.38
52-wk Low
€3.10

Latest Key Developments (Source: Significant Developments)

AB Science Raises EUR 10 Mln In Private Placement
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - AB SCIENCE SA ::ANNOUNCED ON MONDAY THE SUCCESS OF A PRIVATE PLACEMENT.EUR 10.0 MILLION RAISED THROUGH A PRIVATE PLACEMENT OF 2,463,054 NEW ORDINARY SHARES AT A PRICE OF EUR 4.06 .PRIVATE PLACEMENT WITH SUBSCRIPTION WARRANTS ATTACHED, GIVING RIGHT TO PURCHASE ADDITIONAL OF UP TO 1,231,527 SHARES AT EXERCISE PRICE OF EUR 5.50.WARRANTS SHALL BE EXERCISABLE WITHIN 5 YEARS FROM THEIR ISSUANCE AND NOT FREELY TRANSFERABLE .WARRANTS WILL NOT BE LISTED ON EURONEXT PARIS .IF ALL THE WARRANTS ARE EXERCISED, THE COMPANY WOULD RECEIVE AN ADDITIONAL EUR 6.7 MILLION OF PROCEEDS.  Full Article

AB Science Announces The Publication Of The Positive Phase 2/3 Clinical Trial With Masitinib
Monday, 8 Jul 2019 

July 8 (Reuters) - AB Science SA ::Reg-AB SCIENCE ANNOUNCES THE PUBLICATION OF THE POSITIVE PHASE 2/3 CLINICAL TRIAL WITH MASITINIB IN ALS IN THE JOURNAL AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION.STUDY AB10015 REACHED ITS PRIMARY ENDPOINT AND SHOWED THAT MASITINIB AT 4.5 MG/KG/DAY IN COMBINATION WITH RILUZOLE WAS ABLE TO SIGNIFICANTLY (P-VALUE < 0.05) SLOW ALSFRS-R DECLINE BY 27% AS COMPARED WITH THE ACTIVE RILUZOLE CONTROL AT WEEK 48.KEY SECONDARY ENDPOINT, PFS (A TIME-TO-EVENT ANALYSIS, MEASURING THE EARLIEST EVENT BETWEEN DEATH AND FUNCTIONAL DECLINE OF AT LEAST 9 POINTS IN ALSFRS-R)5, WAS ALSO STATISTICALLY SIGNIFICANT (P<0.05), WITH A CLINICALLY MEANINGFUL 25% DELAY IN PROGRESSION (MEDIAN PFS OF 20.0 MONTHS FOR MASITINIB AS COMPARED TO 16.0 MONTHS FOR CONTROL).OTHER SECONDARY ENDPOINTS WERE ALSO SIGNIFICANT (P<0.05), with a 29% SLOWING OF DETERIORATION IN QUALITY-OFLIFE (ALSAQ-40) AND A 22% SLOWING OF DETERIORATION IN RESPIRATORY FUNCTION (FVC).SAFETY WAS ACCEPTABLE AND CONSISTENT WITH MASITINIB’S KNOWN RISK PROFILE.  Full Article

AB Science: Validation Of AB8939 Clinical Development Plan Through Regulatory Authority Scientific Advice Procedure
Thursday, 4 Jul 2019 

July 4 (Reuters) - AB SCIENCE SA ::AB SCIENCE : VALIDATION OF THE AB8939 CLINICAL DEVELOPMENT PLAN THROUGH REGULATORY AUTHORITY SCIENTIFIC ADVICE PROCEDURE.AB8939 IS A NEW GENERATION MICROTUBULE DESTABILIZER, 100% OWNED BY AB SCIENCE, THAT HAS PROMISING POTENTIAL IN ONCOLOGY.AB8939 IS 100 TIMES MORE POTENT THAN DOXORUBICIN (ADRIAMYCIN), WHICH IS A REFERENCE DRUG IN AML.AB8939 IS NOT DEACTIVATED BY MYELOPEROXIDASE ENZYME, WHICH IS AN ADVANTAGE OVER VINCA ALKALOIDS (VINCRISTINE OR VINBLASTINE).  Full Article

AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005
Wednesday, 12 Jun 2019 

June 13 (Reuters) - AB SCIENCE SA ::ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER.STUDY AB12005 IS INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 CONFIRMATORY STUDY OF MASITINIB IN FIRST-LINE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER PATIENTS WITH PAIN AT BASELINE OR TAKING OPIOIDS.PROBABILITY OF SUCCESS OF STUDY AB12005 IS ABOVE 80% IN THE SELECTED SUB-POPULATION.CO EXPECTS TO REPORT THE FINAL RESULTS FROM STUDY AB12005 IN 2020.  Full Article

AB Science Announces Lifting Of ANSM Clinical Hold
Tuesday, 28 May 2019 

May 28 (Reuters) - AB SCIENCE SA ::AB SCIENCE ANNOUNCES THE LIFTING OF THE ANSM CLINICAL HOLD.  Full Article

AB Science FY Operating Loss Stable At 28.9 Million Euros
Tuesday, 30 Apr 2019 

April 30 (Reuters) - AB SCIENCE SA ::AB SCIENCE REPORTS TODAY ITS ANNUAL FINANCIALS AS OF 31 DECEMBER 2018 AND PROVIDES AN UPDATE ON ITS ACTIVITIES.CASH POSITION OF 11.6MEUR AS OF 31 DECEMBER 2018, PLUS 5.7MEUR OF 2018 TAX CREDIT.NET LOSS OF 26.1M€ FOR THE YEAR 2018.FY OPERATING LOSS EUR 28.9 MILLION VERSUS LOSS OF EUR 28.4 MILLION YEAR AGO.FY NET REVENUES EUR 1.7 MILLION VERSUS EUR 1.7 MILLION YEAR AGO.  Full Article

Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE.‍FINAL RESULTS OF STUDY ARE EXPECTED IN Q2 2019​.‍IDMC DID NOT REPORT ANY SAFETY CONCERN WITH MASITINIB IN STUDY POPULATION​.  Full Article

BRIEF-AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005

* ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER